(Q33786256)

29 July 2017

1 reference

title

Screening for prostate cancer. The challenge of promoting informed decision making in the absence of definitive evidence of effectiveness (English)

1 reference

29 July 2017

1 reference

1 reference

Burack RC

1

1 reference

29 July 2017

Wood DP Jr

series ordinal

2

1 reference

29 July 2017

publication date

1 November 1999

1 reference

Medical Clinics of North America

29 July 2017

published in

1 reference

29 July 2017

volume

83

1 reference

29 July 2017

issue

6

1 reference

29 July 2017

page(s)

1423-42, vi

1 reference

Competing risk analysis of men aged 55 to 74 years at diagnosis managed conservatively for clinically localized prostate cancer

29 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970173-5

Determinants of prostate-specific antigen test use in prostate cancer screening by primary care physicians

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970173-5

A critique of the decision analysis for clinically localized prostate cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970173-5

Selection of optimal prostate specific antigen cutoffs for early detection of prostate cancer: receiver operating characteristic curves.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970173-5

Prostate cancer detection in men with serum PSA concentrations of 2.6 to 4.0 ng/mL and benign prostate examination. Enhancement of specificity with free PSA measurements

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970173-5

Early detection of prostate cancer. Part I: Prior probability and effectiveness of tests. The American College of Physicians

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970173-5

Should Medicare provide reimbursement for prostate-specific antigen testing for early detection of prostate cancer? Part II: Early detection strategies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970173-5

The effect of digital rectal examination on prostate-specific antigen levels

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970173-5

National trends in the epidemiology of prostate cancer, 1973 to 1994: evidence for the effectiveness of prostate-specific antigen screening

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970173-5

American College of Preventive Medicine practice policy. Screening for prostate cancer in American men

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970173-5

The importance of patient preference in the decision to screen for prostate cancer. Prostate Patient Outcomes Research Team

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970173-5

Influence of urological morbidity on quality of life in patients with prostate cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970173-5

Prostate cancer screening and beliefs about treatment efficacy: a national survey of primary care physicians and urologists

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970173-5

Patient-re ported complications and follow-up treatment after radical prostatectomy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970173-5

Outcomes of external-beam radiation therapy for prostate cancer: a study of Medicare beneficiaries in three surveillance, epidemiology, and end results areas.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970173-5

Radical retropubic prostatectomy outcomes at a community hospital

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970173-5

Patterns of inheritance and outcome in patients treated with external beam radiation for prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970173-5

Attitudes and practices of primary care physicians for prostate cancer screening.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970173-5

High 10-year survival rate in patients with early, untreated prostatic cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970173-5

7 January 2021

Cancer statistics, 1999.

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970173-5

High rates of prostate-specific antigen testing in men with evidence of benign prostatic hyperplasia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970173-5

Interpreting results of prostate-specific antigen testing for early detection of prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970173-5

Defining and updating the American Cancer Society guidelines for the cancer-related checkup: prostate and endometrial cancers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970173-5

The results of a five-year early prostate cancer detection intervention. Investigators of the American Cancer Society National Prostate Cancer Detection Project

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970173-5

American Cancer Society--National Prostate Cancer Detection Project. Results from multiple examinations using transrectal ultrasound, digital rectal examination, and prostate specific antigen

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970173-5

Adenocarcinoma of the prostate in cystoprostatectomy specimens removed for bladder cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970173-5

Age-specific reference ranges for serum prostate-specific antigen in black men.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970173-5

Risk factors for prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970173-5

Brachytherapy for clinically localized prostate cancer: results at 7- and 8-year follow-up

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970173-5

Effect of patient age on early detection of prostate cancer with serum prostate-specific antigen and digital rectal examination.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970173-5

Decline in prostate cancer mortality from 1980 to 1997, and an update on incidence trends in Olmsted County, Minnesota

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970173-5

Prostate-specific antigen: critical issues for the practicing physician

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970173-5

Age and racial distribution of prostatic intraepithelial neoplasia.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970173-5

Epidemiology of high grade prostatic intraepithelial neoplasia.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970173-5

Evaluation of the digital rectal examination as a screening test for prostate cancer. Rotterdam section of the European Randomized Study of Screening for Prostate Cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970173-5

Interexaminer variability of digital rectal examination in detecting prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970173-5

The early detection of prostate carcinoma with prostate specific antigen: the Washington University experience

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970173-5

The effect of ejaculation on prostate-specific antigen in a prostate cancer-screening population

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970173-5

Population-based prostate cancer trends in the United States: patterns of change in the era of prostate-specific antigen

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970173-5

Significance of high-grade prostatic intraepithelial neoplasia on needle biopsy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970173-5

The impact of informed consent on patient interest in prostate-specific antigen screening

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970173-5

10.1016/S0025-7125(05)70173-5

7 January 2021

Identifiers

DOI

1 reference

29 July 2017

1 reference